Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IMVT

Immunovant Inc

Feb 04 • 04:00PM ET

20.91

Dollar change +0.11
Percentage change 0.53	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA REGN VRTX BMRN CRSP SRPT NTLA RARE EDIT ARCT

| Held by: VTI VB IWM VBR XBI VXF IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.22	Insider Own	59.69%	Shs Outstand	146.57M	Perf Week	-5.08%
Market Cap	3.55B	Forward P/E	-	EPS next Y	-3.17	Insider Trans	19.74%	Shs Float	68.46M	Perf Month	-16.99%
Income	-323.01M	PEG	-	EPS next Q	-0.75	Inst Own	46.17%	Short Float	18.74%	Perf Quarter	-28.54%
Sales	0.00M	P/S	-	EPS this Y	-52.83%	Inst Trans	6.10%	Short Ratio	12.49	Perf Half Y	-24.97%
Book/sh	3.06	P/B	6.82	EPS next Y	-10.39%	ROA	-79.97%	Short Interest	12.83M	Perf Year	-42.03%
Cash/sh	2.78	P/C	7.51	EPS next 5Y	-22.52%	ROE	-92.17%	52W Range	20.48 - 39.55	Perf YTD	-15.58%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-71.93%	52W High	-47.13%	Beta	0.67
Dividend TTM	-	Quick Ratio	7.61	Sales past 5Y	0.00%	Gross Margin	-	52W Low	2.10%	ATR (14)	1.05
Dividend Ex-Date	-	Current Ratio	7.61	EPS Y/Y TTM	-12.81%	Oper. Margin	-	RSI (14)	28.70	Volatility	3.70% 4.68%
Employees	207	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.15	Target Price	51.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-66.55%	Payout	-	Rel Volume	1.27	Prev Close	20.80
Sales Surprise	-	EPS Surprise	-23.29%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	1.03M	Price	20.91
SMA20	-8.90%	SMA50	-17.46%	SMA200	-25.40%	Trades		Volume	1,302,850	Change	0.53%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-10-24	Resumed	Raymond James	Outperform	$36
Oct-09-24	Reiterated	Oppenheimer	Outperform	$47 → $53
Mar-28-24	Initiated	Oppenheimer	Outperform	$50
Mar-13-24	Initiated	Goldman	Buy	$50
Feb-20-24	Initiated	JP Morgan	Overweight	$51
Feb-15-24	Initiated	Wolfe Research	Outperform	$55
Dec-12-23	Initiated	Deutsche Bank	Buy	$50
Oct-13-23	Upgrade	UBS	Neutral → Buy	$18 → $55
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$40
May-01-23	Initiated	BofA Securities	Buy	$26
Apr-25-23	Initiated	Citigroup	Buy	$28
Mar-31-23	Initiated	Piper Sandler	Overweight	$28
Mar-30-23	Initiated	Stifel	Buy	$28
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight	$30
Feb-13-23	Upgrade	Guggenheim	Neutral → Buy	$30
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$10 → $27
Sep-26-22	Downgrade	UBS	Buy → Neutral	$7 → $5
Dec-08-21	Initiated	Wells Fargo	Equal Weight	$9
Aug-03-21	Downgrade	Robert W. Baird	Outperform → Neutral	$20 → $10

Show Previous Ratings

Jan-30-25 05:03PM	Heres Why Immunovant, Inc. (IMVT) Will Double in 2025 (Insider Monkey)
Jan-17-25 11:10AM	Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-16-25 08:45AM	Roivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million each (GuruFocus.com)
Jan-13-25 08:00AM	Immunovant Announces $450 Million Private Placement (GlobeNewswire)
Dec-20-24 07:20AM	Immunovant price target lowered to $45 from $47 at Wells Fargo (TipRanks)
05:31PM	Loading…
Nov-21-24 05:31PM	Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-13-24 03:05AM	Q2 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Nov-07-24 06:30AM	Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 (GlobeNewswire)
Oct-29-24 06:30AM	Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting (GlobeNewswire)
Oct-01-24 09:58AM	Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip? (Insider Monkey)
Sep-30-24 11:12AM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy? (Insider Monkey)
Sep-09-24 12:54PM	What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? (Benzinga) -7.61%
09:13AM	Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses (Pharmaceutical Technology)
07:00AM	Roivant Provides Update on Graves' Disease Development Program (GlobeNewswire)
03:55AM	Immunovant Provides Update on Graves' Disease Development Program (GlobeNewswire)
11:31AM	Loading…
Sep-05-24 11:31AM	Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report? (Zacks) +9.55%
06:30AM	Immunovant to Host Graves' Disease Program Update on September 9, 2024 (GlobeNewswire)
Aug-09-24 12:20AM	Q1 2025 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 04:05PM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 (GlobeNewswire)
Jun-28-24 11:30AM	Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound? (Zacks)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
02:26AM	Q4 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
May-30-24 04:02PM	After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay (Investor's Business Daily) -10.69%
11:29AM	Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus (Zacks)
07:22AM	Immunovant changes up plans for closely watched autoimmune drugs (BioPharma Dive)
05:53AM	Immunovant shunts next-gen FcRn drug ahead of batoclimab in race to rival Vyvgart (FierceBiotech.com)
May-29-24 09:53PM	IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024 (InvestorPlace)
04:06PM	Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
04:01PM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 (GlobeNewswire)
10:17AM	Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
06:28PM	Loading…
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)
May-13-24 09:55AM	Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet (Zacks)
May-08-24 02:43AM	Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1 (Insider Monkey)
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
07:39AM	Should You Hold Immunovant (IMVT)? (Insider Monkey)
Apr-22-24 11:53AM	Here's Why You Should Add Immunovant (IMVT) to Your Portfolio (Zacks)
Apr-17-24 12:00PM	What Makes Immunovant (IMVT) a New Buy Stock (Zacks) -6.48%
Mar-25-24 03:00PM	Wall Streets Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-21-24 04:45PM	Argenx, Immunovant Soar As Tourmaline Plummets On A Rival's Lackluster Test Results (Investor's Business Daily)
11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Mar-13-24 11:30AM	Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report? (Zacks)
Mar-12-24 07:30AM	Immunovant Awarded U.S. Patent for IMVT-1402 (GlobeNewswire)
Mar-08-24 09:35AM	Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks (Zacks)
Feb-26-24 03:04PM	3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 (InvestorPlace)
Feb-23-24 11:22PM	Immunovant Inc CFO Eva Barnett Sells 2,930 Shares (GuruFocus.com)
Feb-14-24 04:35AM	Immunovant Inc (IMVT) Reports Fiscal Q3 Results: Expands Clinical Programs Amid Rising R&D Costs (GuruFocus.com)
12:29AM	Q3 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Feb-13-24 07:26AM	Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus (Zacks)
Feb-12-24 07:00AM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 (GlobeNewswire)
Feb-06-24 02:38PM	7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 (InvestorPlace)
Jan-22-24 06:07AM	Should You Invest in Immunovant (IMVT)? (Insider Monkey)
Jan-19-24 04:39PM	3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024 (InvestorPlace)
Jan-13-24 03:02AM	Immunovant Inc CFO Eva Barnett Sells 3,515 Shares (GuruFocus.com)
Jan-03-24 08:00AM	Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.33%
Dec-26-23 10:01AM	Immunovant (IMVT) Rose on Positive Clinical Trial (Insider Monkey) +6.53%
Dec-21-23 04:09PM	Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off (Investor's Business Daily) +8.07% +6.09%
11:00AM	Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data (Zacks)
10:57AM	Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% (Benzinga)
06:49AM	Immunovant stakes claim for FcRn niche, posting midphase Graves' data and plotting next steps (FierceBiotech.com)
Dec-20-23 04:30PM	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire) -12.84%
04:30PM	Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire)
Dec-19-23 10:16AM	11 Stocks Insiders and Billionaires Are Crazy About (Insider Monkey)
Dec-01-23 01:01AM	Here's Why Immunovant (IMVT) Outperformed in Q3 (Insider Monkey)
Nov-29-23 10:22AM	Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data (Zacks) +6.19%
Nov-28-23 07:00AM	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire) +7.36%
07:00AM	Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire)
Nov-25-23 11:03AM	Immunovant Inc CEO Peter Salzmann Sells Over 16,000 Shares (GuruFocus.com)
Nov-14-23 12:30AM	Q2 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents) +6.62%
Nov-13-23 08:00AM	Immunovant to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-10-23 07:19AM	Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus (Zacks)
Nov-09-23 08:17AM	Immunovant Inc (IMVT) Reports Fiscal Q2 Results: R&D Investments Surge Amidst Clinical Progress (GuruFocus.com) -6.23%
07:00AM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023 (GlobeNewswire)
Oct-27-23 11:02PM	Insider Sell: Chief Legal Officer Mark Levine Sells 4,107 Shares of Immunovant Inc (GuruFocus.com)
Oct-13-23 09:50AM	Netflix downgraded, Applied Materials upgraded: Wall Street's top analyst calls (The Fly) +6.04%
Oct-11-23 11:01PM	CFO Eva Barnett Sells 4,557 Shares of Immunovant Inc (IMVT) (GuruFocus.com)
Oct-07-23 01:00AM	CEO Peter Salzmann Sells 5,239 Shares of Immunovant Inc (IMVT) (GuruFocus.com)
Oct-05-23 03:01AM	Sciences Roivant, Director and 10% Owner, Buys 1,526,316 Shares of Immunovant Inc (IMVT) (GuruFocus.com) +7.64%
Oct-02-23 04:52PM	Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -9.77%
Sep-28-23 09:58AM	Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data (Zacks)
Sep-27-23 11:41PM	Immunovant Announces Pricing of $450 Million Common Stock Financing (GlobeNewswire)
04:09PM	Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33% (Investor's Business Daily)
04:06PM	Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering (Investor's Business Daily)
12:25PM	Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% (Investor's Business Daily)
12:21PM	Why Immunovant Stock Is Bolting Higher Today (Motley Fool)
09:25AM	Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data (Zacks)
Sep-26-23 05:00PM	Immunovant Announces Proposed Offering of $300 Million of Common Stock (GlobeNewswire) +97.04%
04:13PM	Immunovant Doubles And Slugs Argenx As Autoimmune Disease Battle Heats Up (Investor's Business Daily)
04:06PM	Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations (Investopedia)
03:23PM	Why Shares of Immunovant Are Soaring on Tuesday (Motley Fool)
02:26PM	Rebel's Edge - September 26: $IMVT, $PLRX, $UNFI, and The PAC12 (TheStreet.com)
10:01AM	Immunovant Soars 73% And Slugs Argenx As Autoimmune Disease Battle Heats Up (Investor's Business Daily)
09:10AM	These 2 Biotech Stocks Are Bucking a Down Market Tuesday (Motley Fool)
06:00AM	Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results (GlobeNewswire)
Sep-25-23 11:01PM	Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023 (GlobeNewswire)
Aug-17-23 09:31AM	15 Best-Performing Stocks in the Last 12 Months (Insider Monkey) -5.09%
Aug-12-23 08:25AM	We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate (Simply Wall St.)
Aug-11-23 11:20AM	Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus (Zacks)
Aug-10-23 07:00AM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023 (GlobeNewswire) +6.69%

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stout Jay S	Chief Technology Officer	Jan 22 '25	Sale	23.59	2,195	51,780	139,991	Jan 24 04:23 PM
Geffner Michael	Chief Medical Officer	Jan 22 '25	Sale	23.59	2,657	62,679	132,314	Jan 24 04:22 PM
Macias William L.	Chief Medical Officer	Jan 15 '25	Sale	23.83	2,383	56,782	359,408	Jan 17 04:07 PM
Barnett Eva Renee	Chief Financial Officer	Jan 15 '25	Sale	23.83	2,298	54,757	324,766	Jan 17 04:05 PM
Salzmann Peter	Chief Executive Officer	Jan 15 '25	Sale	23.83	8,767	208,900	964,225	Jan 17 04:04 PM
Roivant Sciences Ltd.	Director	Jan 13 '25	Buy	20.00	16,845,010	336,900,200	96,650,341	Jan 15 04:36 PM
Barnett Eva Renee	Chief Financial Officer	Jan 08 '25	Sale	24.10	4,105	98,930	327,064	Jan 10 04:12 PM
Salzmann Peter	Chief Executive Officer	Jan 08 '25	Sale	24.10	5,105	123,030	972,992	Jan 10 04:11 PM
Pande Atul	Director	Dec 02 '24	Sale	28.54	7,750	221,185	86,663	Dec 04 04:22 PM
Hughes Douglas J.	Director	Dec 02 '24	Sale	28.54	5,425	154,830	119,585	Dec 04 04:20 PM
DOUGLAS J. HUGHES	Officer	Dec 02 '24	Proposed Sale	28.20	5,425	152,985		Dec 02 04:33 PM
ATUL CHANDRA PANDE	Director	Dec 02 '24	Proposed Sale	28.20	7,750	218,550		Dec 02 04:33 PM
Levine Mark S.	Chief Legal Officer	Nov 20 '24	Sale	25.45	3,650	92,892	319,228	Nov 22 04:12 PM
Macias William L.	Chief Medical Officer	Nov 20 '24	Sale	25.45	3,353	85,334	361,791	Nov 22 04:11 PM
Barnett Eva Renee	Chief Financial Officer	Nov 20 '24	Sale	25.45	4,174	106,228	331,169	Nov 22 04:09 PM
Salzmann Peter	Chief Executive Officer	Nov 20 '24	Sale	25.45	16,692	424,811	978,097	Nov 22 04:08 PM
Levine Mark S.	Chief Legal Officer	Oct 23 '24	Sale	29.53	4,361	128,780	322,878	Oct 25 04:25 PM
Geffner Michael	Chief Medical Officer	Oct 23 '24	Sale	29.53	3,189	94,171	134,971	Oct 25 04:23 PM
Stout Jay S	Chief Technology Officer	Oct 23 '24	Sale	29.53	2,740	80,912	142,186	Oct 25 04:21 PM
Salzmann Peter	Chief Executive Officer	Oct 16 '24	Sale	28.79	9,095	261,845	994,789	Oct 18 04:31 PM
Macias William L.	Chief Medical Officer	Oct 16 '24	Sale	28.79	3,188	91,783	365,144	Oct 18 04:30 PM
Levine Mark S.	Chief Legal Officer	Oct 16 '24	Sale	28.79	2,860	82,339	327,239	Oct 18 04:28 PM
Barnett Eva Renee	Chief Financial Officer	Oct 16 '24	Sale	28.79	3,271	94,172	335,343	Oct 18 04:27 PM
Barnett Eva Renee	Chief Financial Officer	Oct 09 '24	Sale	29.56	5,162	152,589	338,614	Oct 11 04:04 PM
Salzmann Peter	Chief Executive Officer	Oct 09 '24	Sale	29.56	4,460	131,838	1,003,884	Oct 11 04:02 PM
Levine Mark S.	Chief Legal Officer	Aug 21 '24	Sale	31.86	3,295	104,976	330,099	Aug 23 04:15 PM
Macias William L.	Chief Medical Officer	Aug 21 '24	Sale	31.86	3,027	96,437	368,332	Aug 23 04:14 PM
Barnett Eva Renee	Chief Financial Officer	Aug 21 '24	Sale	31.86	3,768	120,045	343,776	Aug 23 04:11 PM
Butchko Julia G.	Chief Development Officer	Aug 21 '24	Sale	31.86	3,027	96,437	440,959	Aug 23 04:10 PM
Salzmann Peter	Chief Executive Officer	Aug 21 '24	Sale	31.86	15,068	480,052	1,008,344	Aug 23 04:07 PM
Stout Jay S	Chief Technology Officer	Jul 24 '24	Sale	27.76	2,813	78,089	144,926	Jul 26 04:20 PM
Geffner Michael	Chief Medical Officer	Jul 24 '24	Sale	27.76	3,456	95,939	138,160	Jul 26 04:19 PM
Levine Mark S.	Chief Legal Officer	Jul 24 '24	Sale	27.76	4,015	111,456	333,394	Jul 26 04:17 PM
Levine Mark S.	Chief Legal Officer	Jul 17 '24	Sale	29.69	2,505	74,382	337,409	Jul 19 05:42 PM
Macias William L.	Chief Medical Officer	Jul 17 '24	Sale	29.69	3,044	90,386	371,359	Jul 19 05:41 PM
Barnett Eva Renee	Chief Financial Officer	Jul 17 '24	Sale	29.69	3,123	92,733	347,544	Jul 19 05:39 PM
Butchko Julia G.	Chief Development Officer	Jul 17 '24	Sale	29.69	2,867	85,132	443,986	Jul 19 05:38 PM
Salzmann Peter	Chief Executive Officer	Jul 17 '24	Sale	29.69	8,685	257,887	1,023,412	Jul 19 05:36 PM
Barnett Eva Renee	Chief Financial Officer	Jul 09 '24	Sale	28.06	4,747	133,201	350,667	Jul 10 05:07 PM
Butchko Julia G.	Chief Development Officer	Jul 09 '24	Sale	28.06	1,527	42,848	446,853	Jul 10 05:06 PM
Salzmann Peter	Chief Executive Officer	Jul 09 '24	Sale	28.06	4,619	129,609	1,032,097	Jul 10 05:04 PM
Barnett Eva Renee	Chief Financial Officer	May 22 '24	Sale	29.65	4,042	119,845	355,414	May 24 04:18 PM
Salzmann Peter	Chief Executive Officer	May 22 '24	Sale	29.65	16,163	479,233	1,036,716	May 24 04:15 PM
Butchko Julia G.	Chief Development Officer	May 22 '24	Sale	29.65	3,247	96,274	448,380	May 24 04:14 PM
Macias William L.	Chief Medical Officer	May 22 '24	Sale	29.65	3,247	96,274	374,403	May 24 04:13 PM
Levine Mark S.	Chief Legal Officer	May 22 '24	Sale	29.65	3,242	96,125	339,914	May 24 04:10 PM
Geffner Michael	Chief Medical Officer	Apr 24 '24	Sale	28.90	3,261	94,243	141,616	Apr 26 05:22 PM
Stout Jay S	Chief Technology Officer	Apr 24 '24	Sale	28.90	7,239	209,207	147,739	Apr 26 05:20 PM
Levine Mark S.	Chief Legal Officer	Apr 24 '24	Sale	28.90	3,963	114,531	343,156	Apr 26 05:18 PM
Levine Mark S.	Chief Legal Officer	Apr 17 '24	Sale	29.06	9,827	285,554	347,119	Apr 19 06:06 PM
Macias William L.	Chief Medical Officer	Apr 17 '24	Sale	29.06	8,280	240,602	377,650	Apr 19 06:05 PM
Barnett Eva Renee	Chief Financial Officer	Apr 17 '24	Sale	29.06	12,253	356,049	359,456	Apr 19 06:01 PM
Butchko Julia G.	Chief Development Officer	Apr 17 '24	Sale	29.06	10,115	293,923	451,627	Apr 19 05:59 PM
Salzmann Peter	Chief Executive Officer	Apr 17 '24	Sale	29.06	34,079	990,269	1,052,879	Apr 19 05:57 PM
Barnett Eva Renee	Chief Financial Officer	Apr 09 '24	Sale	31.18	3,689	115,023	371,709	Apr 10 04:18 PM
Butchko Julia G.	Chief Development Officer	Apr 09 '24	Sale	31.18	1,053	32,833	461,742	Apr 10 04:16 PM
Salzmann Peter	Chief Executive Officer	Apr 09 '24	Sale	31.18	4,807	149,882	1,086,958	Apr 10 04:14 PM
Barnett Eva Renee	Chief Financial Officer	Feb 22 '24	Sale	36.15	2,930	105,920	320,420	Feb 23 04:21 PM
Levine Mark S.	Chief Legal Officer	Feb 22 '24	Sale	36.15	2,134	77,144	301,968	Feb 23 04:18 PM
Macias William L.	Chief Medical Officer	Feb 22 '24	Sale	36.15	2,221	80,289	330,952	Feb 23 04:16 PM
Butchko Julia G.	Chief Development Officer	Feb 22 '24	Sale	36.15	2,146	77,578	407,817	Feb 23 04:14 PM
Salzmann Peter	Chief Executive Officer	Feb 22 '24	Sale	36.15	13,454	486,362	931,231	Feb 23 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMVT

Immunovant Inc

Upgrade your FINVIZ experience